- Home
- SOTK vs PLX Comparison
SOTK vs PLX Comparison
Compare SOTK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOTK
- PLX
- Stock Information
- Founded
- SOTK 1975
- PLX 1993
- Country
- SOTK United States
- PLX Israel
- Employees
- SOTK N/A
- PLX N/A
- Industry
- SOTK Industrial Machinery/Components
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOTK Technology
- PLX Health Care
- Exchange
- SOTK Nasdaq
- PLX Nasdaq
- Market Cap
- SOTK 67.7M
- PLX 79.4M
- IPO Year
- SOTK 1987
- PLX 1998
- Fundamental
- Price
- SOTK $4.47
- PLX $1.40
- Analyst Decision
- SOTK Buy
- PLX Strong Buy
- Analyst Count
- SOTK 1
- PLX 1
- Target Price
- SOTK $10.00
- PLX $10.00
- AVG Volume (30 Days)
- SOTK 7.2K
- PLX 225.7K
- Earning Date
- SOTK 10-15-2024
- PLX 11-14-2024
- Dividend Yield
- SOTK N/A
- PLX N/A
- EPS Growth
- SOTK 85.72
- PLX N/A
- EPS
- SOTK 0.09
- PLX N/A
- Revenue
- SOTK $20,650,571.00
- PLX $38,053,000.00
- Revenue This Year
- SOTK $6.08
- PLX N/A
- Revenue Next Year
- SOTK $12.36
- PLX $88.94
- P/E Ratio
- SOTK $50.00
- PLX N/A
- Revenue Growth
- SOTK 25.27
- PLX N/A
- 52 Week Low
- SOTK $3.50
- PLX $0.82
- 52 Week High
- SOTK $6.12
- PLX $1.90
- Technical
- Relative Strength Index (RSI)
- SOTK 58.03
- PLX 67.67
- Support Level
- SOTK $4.21
- PLX $1.14
- Resistance Level
- SOTK $4.46
- PLX $1.34
- Average True Range (ATR)
- SOTK 0.13
- PLX 0.07
- MACD
- SOTK -0.00
- PLX 0.01
- Stochastic Oscillator
- SOTK 100.00
- PLX 97.06
About SOTK Sono-Tek Corporation
Sono-Tek Corp designs and manufactures ultrasonic coating systems that apply precise, thin film coatings to a multitude of products for the microelectronics/electronics, alternative energy, medical, and industrial markets, including specialized glass applications in construction and automotive. It sells products to emerging research and development and other markets. Its ultrasonic nozzle systems use high-frequency, ultrasonic vibrations that atomize liquids into minute drops that can be applied to surfaces at low velocity providing thin layers of protective materials over a surface such as glass or metals.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.